Top 7 in oncology
A snapshot of the most highly ranked articles in oncology, from Faculty of 1000
linkurl:1. Donor match not needed;http://f1000.com/8451957?key=xspfhy56z9z65h3
Elderly acute myeloid leukemia patients who received blood stem cells from non-matching donors after chemotherapy showed marked improvement over patients receiving chemo alone.
M. Guo et al., "Infusion of HLA-mismatched peripheral blood stem cells improves the outcome of chemotherapy for acute myeloid leukemia in elderly patients," linkurl:__Blood,__;http://www.ncbi.nlm.nih.gov/sites/entrez/20966170?dopt=Abstract&holding=f1000%2Cf1000m 117:936-41, 2011. Evaluated by Arati Rao, Duke Univ; Riccardo Varaldo, U of Genova and S Martino Hosp, Italy; Nelson Chao, Duke Univ Med Cntr. linkurl:Free F1000 Evaluation;http://f1000.com/8451957?key=xspfhy56z9z65h3
linkurl:2. Weighing brain radiation therapy;http://f1000.com/7508964?key=bcj5t4djf63y7qx
Clinicians have debated whether whole-brain radiation therapy (WBRT) is the appropriate follow-up therapy for CNS lymphoma, a cancer of the immune cells in the brain, because of its relatively high risk of toxicity. A clinical trial suggested that WBRT should not be given to patients who respond well to methotrexate, a first-line drug against the disease, but might improve overall survival for those who don't, though the results lacked statistical significance.
E. Thiel et al., High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial," linkurl:__Lancet Oncol,__;http://www.ncbi.nlm.nih.gov/sites/entrez/20970380?dopt=Abstract&holding=f1000%2Cf1000m 11:1036-47, 2010. Evaluated by Priya Kumthekar and Jeffrey Raizer, Northwestern Univ; Roger Abounader and David Schiff, U of Virginia Neuro-Oncology Cntr. linkurl:Free F1000 Evaluation;http://f1000.com/7508964?key=bcj5t4djf63y7qx
linkurl:3. Estimating breast cancer survival;http://f1000.com/9407956?key=pxl81y59j917nqc
Image: Wikimedia/ PLoS Biol
Researchers compiled data from more than 13,000 women with metastatic breast cancer in order to provide patients a more detailed answer about their chances of survival, and to provide clinicians with a guide on how to communicate the information.
B.E. Kiely et al., "How long have I got? Estimating typical, best-case, and worst-case scenarios for patients starting first-line chemotherapy for metastatic breast cancer: a systematic review of recent randomized trials," linkurl:__J Clin Oncol,__;http://www.ncbi.nlm.nih.gov/sites/entrez/21189397?dopt=Abstract&holding=f1000%2Cf1000m 29:456-63, 2011. Evaluated by Michael Fisch, U of Texas, MD Anderson Cancer Cntr. linkurl:Free F1000 Evaluation;http://f1000.com/9407956?key=pxl81y59j917nqc
linkurl:4. Details improve prognosis estimates;http://f1000.com/9390956?key=8q65jpxdb6kxtqv
Because mammography can detect breast tumors earlier than other detection means and can give clinicians more precise information, patients whose tumors were identified with mammograms had increased survival. The results suggest that how a cancer is detected should be factored in when communicating the certainty of a prognosis.
S. Mook et al., "Independent Prognostic Value of Screen Detection in Invasive Breast Cancer," linkurl:__J Natl Cancer Inst,__;http://www.ncbi.nlm.nih.gov/sites/entrez/21350218?dopt=Abstract&holding=f1000%2Cf1000m 103:585-97, 2011. Evaluated by Alberto Quaglia National Cancer Res Inst, Italy. linkurl:Free F1000 Evaluation;http://f1000.com/9390956?key=8q65jpxdb6kxtqv
linkurl:5. The genetics of a germline cancer;http://f1000.com/9312958?key=pyf7yvdcqj6rj56
Researchers honed the genetic basis of multiple endocrine neoplasia type 2, a hereditary cancer involving the gene RET. The data may help clinicians stratify patients into different groups based on type of RET mutation, which could influence treatment decisions.
K. Frank-Raue et al., "Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10," linkurl:__Hum Mutat,__;http://www.ncbi.nlm.nih.gov/sites/entrez/20979234?dopt=Abstract&holding=f1000%2Cf1000m 32:51-58, 2011. Evaluated by Rute Tomaz, Jaime Miguel Gomes Pita and Branca Cavaco, Inst Portugues de Oncologia de Lisboa, Portugal. linkurl:Free F1000 Evaluation;http://f1000.com/9312958?key=pyf7yvdcqj6rj56
linkurl:6. Kill all tumor cells;http://f1000.com/9247956?key=y2rcxvw14z2cprj
Patient leukemias transplanted into mice reveal that not only will the most aggressive cells within a tumor cause disease, but less aggressive and genetically distinct cells may also increase in number and cause disease, suggesting that therapies should aim to eradicate all tumor cells, not just the prevailing clone.
F. Notta et al., "Evolution of human BCR-ABL1 lymphoblastic leukaemia-initiating cells," linkurl:__Nature__;http://www.ncbi.nlm.nih.gov/sites/entrez/21248843?dopt=Abstract&holding=f1000%2Cf1000m 469:362-67, 2011. Evaluated by Anil Sadarangani and Catriona Jamieson, UCSD. linkurl:Free F1000 Evaluation;http://f1000.com/9247956?key=y2rcxvw14z2cprj
linkurl:7. Microtubule inhibitors extend survival;http://f1000.com/9304956?key=33bnr9804x10c2h
Microtubule deregulation is one of the hallmarks of cancer cells, whose cytoplasms become overrun with filaments. Patients with metastatic breast cancer have about a 3-month increase in patient survival when treated with the microtubule inhibitor, eribulin, which initiates cancer cell death by blocking cell division
J. Cortes et al., "Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study," linkurl:__Lancet__;http://www.ncbi.nlm.nih.gov/sites/entrez/21376385?dopt=Abstract&holding=f1000%2Cf1000m 377:914-23, 2011. Evaluated by Blair Irwin and Jeffrey Peppercorn, Duke Univ. linkurl:Free F1000 Evaluation;http://f1000.com/9304956?key=33bnr9804x10c2h
The F1000 Top 7 is a snapshot of the highest ranked articles from a 30-day period on Faculty of 1000 in Oncology, as calculated on April 7, 2011. Faculty Members evaluate and rate the most important papers in their field. To see the latest rankings, search the database, and read daily evaluations, visit linkurl:http://f1000.com.;http://f1000.com
**__Related stories:__***linkurl:Top 7 in cancer biology;http://www.the-scientist.com/news/display/58092/
[29th March 2011]*linkurl:Top 7 in medicine;http://www.the-scientist.com/news/display/58084/
[22nd March 2011]*linkurl:Top 7 in immunology;http://www.the-scientist.com/news/display/58041/
[8th March 2011]